Loading company
Anaptysbio, Inc.
ANAB · Nasdaq · ·
Next earnings: November 3, 2026
$50.32-1.0%Sep 29 close
- 1M
- -10.6%
- 6M
- +36.3%
- 1Y
- +146.5%
- 5Y
- +180.8%
ANAB · Nasdaq · ·
Next earnings: November 3, 2026
$50.32-1.0%Sep 29 close
Anaptysbio, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $27.5M | $22.3M | +23.47% |
| Profit | $183.9M | -$38.6M | +576.00% |
| Profit per share | $5.34 | -$1.34 | +498.51% |
| Free Cash Flow | -$25.9M | -$10.7M | -141.60% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Following the completion of the spin-off of First Tracks Bio in late April, Anaptys now exclusively manages the financial collaborations for Jemperli and imsidolimab, with streamlined operations requiring limited FTEs, minimal operating expenses and delivering an EBIT margin greater than 95%,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Anaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Anaptysbio, Inc.’s Item 2.02 8-K filed May 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Anaptysbio, Inc. has no earnings call transcript available.